Technology Transfer Office

Available Technologies

Human leucine-rich A-2-glycoprotein-1 and aminopeptidase N as risk indicators for cancer

Short Description

A diagnostic test which may be used to determine whether an individual or test subject is at risk of developing or having cancer.

Abstract

The present diagnostic tests, which involves assessing levels of LRG1, CD13, or the combination thereof in a urine or serum sample from a test subject, may provide additive predictive value beyond that seen with clinical and diagnostic risk factors currently employed by physicians.

Inventor(s)

Dr. Aimin Zhou, Ph.D. Professor, Department of Chemistry.

Commercial Applications

  • Cancer treatment.

Advantages

  • Non-invasive

  • Not site specific

  • Inexpensive

IP Information

Pending U.S. Application

Related IP

 

Status

Available